Pharmaceutical major Dr Reddy’s Laboratories (DRL) plans to drive future growth through introducing new drugs and differentiated formulations. The company is already researching the development of polypill, anti-cholesterol drug CETP
(cholesterol ester transfer protein) and biosimilars, among others.
“We want to be a company led by the discovery of drugs,” said Anji Reddy, chairman DRL.
The company has completed phase-I of the CETP trials and is entering phase-II, he said.
DRL’s vice-chairman and CEO, GV Prasad said the company would calibrate investments in proprietary products and other high risk R&D to establish financial stability.
“We believe the next wave of growth will come from proprietary products and would like to invest in developing these products,” said Prasad.
The company is eyeing a revenue of $3 billion (Rs 14,000 crore) by 2013. It posted a revenue of $1.37 billion (Rs 6,400 crore) in the last financial year.